How Has the Survanta Market Size Evolved in Recent Years?
The survanta market has seen considerable growth due to a variety of factors.
• Over the past few years, the Survanta market has experienced an XX (HCAGR). It's predicted to increase from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%.
The historic development can be linked to the progression of neonatal care, a surge in preterm deliveries, advancements in the technologies related to respiratory care, enhanced awareness of neonatal lung diseases, and the expansion of healthcare infrastructures in emerging regions.
What Are The Predictions for The Survanta Market Size?
The survanta market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for the survanta market to expand by XX(FCAGR) in the coming years. By 2029, the market is projected to be worth $XX million, with a Compound Annual Growth Rate (CAGR) of XX%.
This predicted growth is largely due to an anticipated increase in the incidence of breathing difficulties in newborns, improvements in surfactant therapy, heightened government focus on newborn health, an upsurge in neonatal intensive care units (NICUs) and more inclusive healthcare services in developing markets. Trends to watch include breakthroughs in newborn care, technological advancements, point-of-care testing, the use of telemedicine in newborn care, and individualized treatment.
What Key Factors and Trends Are Driving The Growth Survanta Market?
The surging incidence of premature births is substantially fueling the expansion of the survanta market going forward. Premature births, defined as the birth of a baby before completion of 37 weeks of pregnancy, result in underdeveloped organs and heightened health hazards. The escalating incidence of premature births can be credited to a range of factors including maturing maternal age, lifestyle decisions, the growing incidence of chronic ailments, and progress in fertility therapies. Survanta is employed in premature births for the treatment of Respiratory Distress Syndrome (RDS), an ailment commonly found in premature infants due to inadequate surfactant production in their lungs, aiding in enhancing lung functionality and mitigating the danger of complications. For example, as per the Centers for Disease Control and Prevention, a government agency based in the US, the proportion of premature live births in England and Wales witnessed a rise to 7.9% in 2022, an increase from 7.5% in 2021. Consequently, the escalating incidence of premature births is steering the growth of the survanta market.
What Are The Core Segments Of The Global Survanta Market?
The survanta market covered in this report is segmented –
1) By Indication: Respiratory Distress Syndrome (RDS), Meconium Aspiration Syndrome (MAS), Bronchopulmonary Dysplasia (BPD), Acute Respiratory Failure, Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Public Health Clinics
3) By End-User: Pediatric
Pre-Book The Survanta Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Who Are the Key Players In The Survanta Market?
Major companies operating in the survanta market are:
• AbbVie Ltd.
What Are The Regional Insights Into The Survanta Market?
North America was the largest region in the survanta market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the survanta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
